31 March 2015, Tuesday, 14:53
UFA, 31 March 2015. /Bashinform News Agency, Arina Rakhimkulova/. Ufa branch research and production association "Microgen" "Immunopreparat" made a trial series of "Epoetin Beta" preparation for treatment of anemia. Specialists of the pharmaceutical company began to introduce the technology of its production in January 2015. Filling of the tested new product in individual sterile syringes in the amount of 6.5 thousand doses took place in the finishing department.
Now a trial series of the drug is being tested in terms of sterility, toxicity, bacterial endotoxins, and physico-chemical parametres. Industrial production of new medicine will begin in April of this year. By the end of the year it is planned to produce 100 thousand doses that will be 10 percent of the market of erythropoietin in Russia.
The "Epoetin Beta" is included in the list of vital and essential drugs for medical use in 2015.
At the moment in the Russian Federation seven trade names of erythropoietin (alpha and beta) in the form of syringes and syringe tubes 2000 IU are registered and operates, among which there are three Russian producers. The total market is over 1 million doses.